GeneDx heads into its third-quarter report with a gap between what has improved on paper and what has improved in its bank account. Last quarter, genome coverage among commercial lives jumped from 47% to roughly 87%, driven largely by the Carelon decision covering about 56 million lives. Yet the outpatient genome collection rate stayed near 32%, well below the 43% of a year earlier, and management said Q3 collections would remain roughly flat. Investors have already been told the payoff arrives later. This report will show whether the early signs of that payoff are visible, and whether the market's growing skepticism is justified.

The Street expects earnings of $0.07 per share on revenue of $122.1 million when GeneDx reports after the close on November 9. Revenue would rise 4.6% from $116.7 million a year ago and about 7% from last quarter's $114.4 million. Earnings would fall roughly 86% from the $0.49 earned a year earlier, which reflects how much average reimbursement has slipped since then. Management guided third-quarter revenue to $122 million to $124 million and reaffirmed its full-year range of $475 million to $490 million. Consensus has dropped from about $124.5 million to the very bottom of that quarterly range. Clearing the bar on revenue is not demanding, but a result only at the low end would leave little room for the fourth-quarter step-up the full-year outlook requires.

The most important figure is blended average revenue per test. It held near $3,300 last quarter, down from about $3,750 for full-year 2025 and $3,800 in the year-ago quarter. Management described that level as stable, and the first thing to confirm is that it did not slip again. A modest increase, even with flat collection rates, would suggest the growing share of genome volume sent to payers with positive policies, 67% last quarter versus 38% a year earlier, is starting to produce cash. Another decline would point the other way. It would suggest that restrictive eligibility rules and administrative denials are blunting the value of the new coverage, a risk management acknowledged directly.

Demand is the more reliable part of the story. Management reaffirmed exome and genome volume growth of at least 30% and noted that reflex orders, where an exome converts to a genome, surpassed standalone genome volume for the first time in July. Volume holding near that pace would support the claim that the business is supply-of-dollars constrained, not demand constrained. Margins matter too. Genome tests cost about twice as much as exomes, and cost per test is expected to stay flat through year-end. More genome mix without better collections could therefore squeeze gross margin. Comments on Medi-Cal managed care plans adopting the new genome rate, and early results from the newly built revenue-cycle team, would help firm up the fourth-quarter case.

Profitability is the other promise to keep. After completing $25 million in cost cuts, management guided to roughly $2 million in adjusted net income for the quarter. The balance sheet, with about $188 million in pro forma liquidity following the debt expansion and Blackstone Life Sciences investment, reduces financing risk. A slip back into losses would still damage confidence in the company's cost discipline.

The market has not been patient. Shares are down 15.7% since the last report, while the S&P 500 fell 1.1%. At $64.09, the stock trades much closer to its post-report low of $55 than its spike to $105.18, and bearish sentiment has deepened from the prior quarter. That lowers the bar somewhat, but it does not change what the report must show. Hitting guidance is the minimum. The narrative stays intact only if management can point to concrete progress, such as higher reimbursement, improving denial rates, or a clear fourth-quarter collection trajectory, showing that broader coverage is finally turning into revenue.